Oncotarget

Research Papers:

MicroRNA-92b inhibits epithelial-mesenchymal transition-induced migration and invasion by targeting Smad3 in nasopharyngeal cancer

Chong Zhao, Feipeng Zhao, Huajun Feng, Shengen Xu and Gang Qin _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:91603-91613. https://doi.org/10.18632/oncotarget.21342

Metrics: PDF 480 views  |   HTML 1122 views  |   ?  


Abstract

Chong Zhao1, Feipeng Zhao1, Huajun Feng1, Shengen Xu1 and Gang Qin1

1Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, P.R. China

Correspondence to:

Gang Qin, email: qingang0823@126.com

Keywords: microRNA-92b, nasopharyngeal carcinoma, Smad3, EMT, invasion

Received: June 21, 2017    Accepted: July 26, 2017    Published: September 27, 2017

ABSTRACT

Increasing studies reports that aberrant miRNAs contribute to nasopharyngeal carcinoma (NPC) development and progression. However, the role of miR-92b in NPC remains unclear. In present research, we found that a reduced miR-92b expression in NPC tissues and cell lines. The clinical data showed that the down-regulated miR-92b expression was obviously associated with adverse prognostic characteristic. Furthermore, we confirmed that miR-92b was a novel independent prognostic symbol for predicting 5-year survival of NPC patients. MiR-92b overexpression inhibited cell migration, invasion and EMT progress, while down-regulated miR-92b reversed the effect. Besides, miR-92b could modulate Smad3 by directly binding to its 3’-UTR. In clinical samples of NPC, miR-92b inversely correlated with Smad3. Alternation of Smad3 expression at least partially abrogated the migration, invasion and EMT progress of miR-92b on NPC cells. In summary, our results indicated that miR-92b functioned as a tumor suppressor gene in regulating the EMT and metastasis of NPC via targeting Smad3, and may represent a novel potential therapeutic target and prognostic marker for NPC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21342